Reaction
Device Operational Issue reporting signals
As of the last recalculation, Device Operational Issue appears in 4,170 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is INSULIN GLARGINE (PRR 76.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Insulin Glargine | 1,990 | 76.1 | 76.7 |
| Dalteparin Sodium | 113 | 54.8 | 55.4 |
| Abatacept | 709 | 30.6 | 30.7 |
| Alirocumab | 137 | 28.2 | 28.3 |
| Insulin Glulisine | 39 | 19.3 | 19.4 |
| Teriparatide | 364 | 17.6 | 17.6 |
| Somatropin | 178 | 12.6 | 12.6 |
| 0Xygen | 66 | 6.8 | 6.8 |
| Oxygen | 66 | 6.8 | 6.8 |
| Insulin Glargine-Yfgn | 28 | 6.4 | 6.4 |
| Insulin Aspart | 66 | 5.0 | 5.1 |
| Treprostinil | 120 | 4.9 | 4.9 |
| Insulin Lispro | 128 | 4.7 | 4.7 |
| Filgrastim | 33 | 4.4 | 4.4 |
| Interferon Beta-1B | 16 | 4.2 | 4.2 |
| Liraglutide | 19 | 1.9 | 1.9 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 1.9 | 1.9 |
| Nintedanib | 11 | 1.8 | 1.8 |
| Dupilumab | 155 | 1.6 | 1.6 |
| Benralizumab | 5 | 1.2 | 1.2 |
| Abaloparatide | 5 | 0.8 | 0.8 |
| Guselkumab | 5 | 0.7 | 0.7 |
| Galcanezumab-Gnlm | 4 | 0.6 | 0.6 |